Literature DB >> 20237849

Alginate-based microfluidic system for tumor spheroid formation and anticancer agent screening.

Michael C W Chen1, Madhuja Gupta, Karen C Cheung.   

Abstract

We demonstrate a microfluidic system for long-term tumor cell culture and drug testing. Three-dimensional cell culture is critical in characterizing anticancer treatments since it may provide a better model than monolayer culture of tumor cells. Breast tumor cells were encapsulated within alginate which was gelled in situ within the microchannels. Tumor spheroid formation was observed several days after cell seeding, and various concentrations of doxorubicin were applied to the encapsulated cell aggregates. Drug effects on cell viability and proliferation were measured. In future, hydrogel-based microfluidic devices can comprise part of systems which replace labor intensive screening platforms currently implemented in the laboratory, and they address a need for improving preclinical testing of cancer cell sensitivity to anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237849     DOI: 10.1007/s10544-010-9417-2

Source DB:  PubMed          Journal:  Biomed Microdevices        ISSN: 1387-2176            Impact factor:   2.838


  19 in total

1.  A microfluidic system for investigation of extravascular transport and cellular uptake of drugs in tumors.

Authors:  Nelita T Elliott; Fan Yuan
Journal:  Biotechnol Bioeng       Date:  2011-12-26       Impact factor: 4.530

2.  Density-dependent separation of encapsulated cells in a microfluidic channel by using a standing surface acoustic wave.

Authors:  Jeonghun Nam; Hyunjung Lim; Choong Kim; Ji Yoon Kang; Sehyun Shin
Journal:  Biomicrofluidics       Date:  2012-05-16       Impact factor: 2.800

3.  Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro.

Authors:  Kévin Alessandri; Bibhu Ranjan Sarangi; Vasily Valérïévitch Gurchenkov; Bidisha Sinha; Tobias Reinhold Kießling; Luc Fetler; Felix Rico; Simon Scheuring; Christophe Lamaze; Anthony Simon; Sara Geraldo; Danijela Vignjevic; Hugo Doméjean; Leslie Rolland; Anette Funfak; Jérôme Bibette; Nicolas Bremond; Pierre Nassoy
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-26       Impact factor: 11.205

Review 4.  Strategies for improving the physiological relevance of human engineered tissues.

Authors:  Rosalyn D Abbott; David L Kaplan
Journal:  Trends Biotechnol       Date:  2015-04-30       Impact factor: 19.536

5.  Cell-laden microengineered pullulan methacrylate hydrogels promote cell proliferation and 3D cluster formation.

Authors:  Hojae Bae; Amir F Ahari; Hyeongho Shin; Jason W Nichol; Che B Hutson; Mahdokht Masaeli; Su-Hwan Kim; Hug Aubin; Seda Yamanlar; Ali Khademhosseini
Journal:  Soft Matter       Date:  2011-01-01       Impact factor: 3.679

6.  Microfluidic device for expedited tumor growth towards drug evaluation.

Authors:  Christopher George Uhl; Yaling Liu
Journal:  Lab Chip       Date:  2019-04-09       Impact factor: 6.799

7.  TISSUE ENGINEERING PERFUSABLE CANCER MODELS.

Authors:  E L Fong; M Santoro; M C Farach-Carson; F K Kasper; A G Mikos
Journal:  Curr Opin Chem Eng       Date:  2014-02       Impact factor: 5.163

Review 8.  Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy.

Authors:  Geeta Mehta; Amy Y Hsiao; Marylou Ingram; Gary D Luker; Shuichi Takayama
Journal:  J Control Release       Date:  2012-05-18       Impact factor: 9.776

9.  A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs.

Authors:  Choong Kim; Junichi Kasuya; Jessie Jeon; Seok Chung; Roger D Kamm
Journal:  Lab Chip       Date:  2015-01-07       Impact factor: 6.799

10.  Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.

Authors:  Bhushan J Toley; Zachary G Tropeano Lovatt; Josephine L Harrington; Neil S Forbes
Journal:  Integr Biol (Camb)       Date:  2013-09       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.